Rapid Reactions
Dr Rugo of the University of California San Francisco Comprehensive Cancer Center reports on the outcomes of a retrospective study of patients with metastatic breast cancer and brain metastases treated with abemaciclib. Read More ›
Dr Tolaney of Dana-Farber Cancer Institute reviews data on HER2CLIMB-02 and contributes future considerations of tucatinib in the metastatic HER2-positive breast cancer setting. Read More ›
Dr Rugo of the University of California San Francisco Comprehensive Cancer Center provides her insights on the practical aspects of the reported results of the INAVO120 phase 3 study. Read More ›
Dr Tolaney of Dana-Farber Cancer Institute discusses her perspectives on the clinically meaningful overall survival outcomes of abemaciclib added to a nonsteroidal aromatase inhibitor as initial therapy in patients with HR+/HER2- advanced breast cancer. Read More ›
Please join Pashtoon Kasi, MD, MS, from Weill Cornell Medicine and Englander Institute of Precision Medicine, as he discusses pivotal presentations from ASCO 2023 focused on metastatic colorectal cancer (mCRC). Read More ›
Please join Pashtoon Kasi, MD, MS, from Weill Cornell Medicine and Englander Institute of Precision Medicine, as he discusses the trends and outcomes of older patients compared to younger patients who received 1L chemotherapy for mCRC. Read More ›
Please join Pashtoon Kasi, MD, MS, from Weill Cornell Medicine and Englander Institute of Precision Medicine, as he describes the outcomes and study design of clinical trials evaluating targeted therapeutic options for patients with mCRC. Read More ›
Pashtoon Kasi, MD, MS, from Weill Cornell Medicine and Englander Institute of Precision Medicine, explores potential best practice approaches to biomarker testing in mCRC. Read More ›
Dr David M. O’Malley, Professor, Department of Obstetrics and Gynecology at The Ohio State University College of Medicine and Director of the Division of Gynecologic Oncology at the OSUCCC – James, discusses his perspectives on the current treatment landscape and optimal clinical management of patients with advanced ovarian cancer who are given PARP-is as maintenance therapy in the first-line setting. Read More ›
Dr. Neil M. Iyengar, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, highlights and addresses potential barriers of clinically and demographically underserved patients with HER2-positive mBC. Read More ›